Pneumococcal polysaccharide revaccination: Immunoglobulin G seroconversion, persistence, and safety in frail, chronically ill older subjects

Journal of the American Geriatrics Society

Volumn 51, Issue 2, 2003, Pages 240-245

  Lackner, Thomas E ^a   Hamilton, Robert G ^b   Hill, John J ^c   Davey, Cynthia ^d   Guay, David R P ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c ABBOTT NORTHWESTERN HOSPITAL   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Aged; Bacterial vaccines; Streptococcus pneumoniae

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; PNEUMOCOCCUS VACCINE;

AGED; ANTIBODY RESPONSE; ARTICLE; CHRONIC DISEASE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEVER; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; NAUSEA; RASH; REVACCINATION; SEROCONVERSION; SEROTYPE; SIDE EFFECT;

AGED; AGED, 80 AND OVER; CHRONIC DISEASE; FEMALE; FOLLOW-UP STUDIES; FRAIL ELDERLY; HUMANS; IMMUNOGLOBULIN G; MALE; PNEUMOCOCCAL VACCINES; PROSPECTIVE STUDIES;

EID: 0037320993     PISSN: 00028614     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1532-5415.2003.51064.x     Document Type: Article

References (34)

1. Butler JC, Schuchat A. Epidemiology of pneumococcal infections in the elderly. Drugs Aging 1999;15(Suppl 1):S11-S19.
2. Fedson DS, Musher DM, Eskola J. Pneumococcal vaccine. In: Plotkin SA, Orenstein WA, eds. Vaccines, 3rd Ed. Philadelphia: W.B. Saunders Co, 1999, pp 553-607.
3. Fedson DS, Scott JAG. The burden of pneumococcal disease among adults in developed and developing countries: What is and is not known. Vaccine 1999;17(Suppl 1):S11-S18.
4. Fedson DS. The clinical effectiveness of pneumococcal vaccination: A brief review. Vaccine 1999;17(Suppl 1):S85-S90.
5. Spika JS, Fedson DS, Facklam RR. Pneumococcal vaccination. Controversies and opportunities. Infect Dis Clin North Am 1990;4:11-27.
6. Bentley DW. Pneumococcal vaccination in the institutionalized elderly: Review of past and recent studies. Rev Infect Dis 1981;3:S61-S70.
7. Breiman RF, Spika JS, Navarro VJ et al. Pneumococcal bacteremia in Charleston County, South Carolina. Arch Intern Med 1990;150:1401-1405.
8. Bennett NM, Buffington J, LaForce FM. Pneumococcal bacteremia in Monroe County, New York. Am J Public Health 1992;82:1513-1516.
9. Plouffe JF, Breiman RF, Facklam RR. Bacteremia with Streptococcus pneumoniae: Implications for therapy and prevention. Franklin County Pneumonia Study Group. JAMA 1996;275:194-198.
10. Feikin DR, Schuchat A, Kolczak M et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000;90:223-229.
11. Whitney CG, Farley MM, Hadler J et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000; 343:1917-1924.
12. Butler JC, Cetron MS. Pneumococcal drug resistance: The new 'special enemy of old age'. Clin Infect Dis 1999;28:730-735.
13. Nuorti JP, Butler JC, Crutcher JM et al. An outbreak of multi-drug resistant pneumococcal pneumonia and bactetemia among unvaccinated nursing home subjects. N Engl J Med 1998;338:1861-1868.
14. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1997;46:1-24.
15. Gaillat J, Zmirou D, Mallaret MR et al. Clinical trial of an antipneumococcal vaccine in elderly subjects living in institutions. Rev Epidemiol Sante Publique 1985;33:437-444.
16. Simberkoff MS, Cross AP, Al-Ibrahim M et al. Efficacy of pneumococcal vaccine in high-risk patients: Results of a Veterans Administration Cooperative study. N Engl J Med 1986;315:1318-1327.
17. Butler JC, Breiman RF, Campbell JF et al. Polysaccharide pneumococcal vaccine efficacy. An evaluation of current recommendations. JAMA 1993;270: 1826-1831.
18. Musher DM, Luchi MJ, Watson DA et al. Pneumococcal polysaccharide vaccine in young adults and older bronchitics: Determination of IgG responses by ELISA and the effect of adsorption of serum with non-type-specific cell wall polysaccharide. J Infect Dis 1990;161:728-735.
19. Koivula I, Sten M, Leinonen M et al. Clinical efficacy of pneumococcal vaccine in the elderly: A randomized, single-blind population-based trial. Am J Med 1997;103:281-290.
20. Ortqvist A, Hedlund J, Burman LA et al. Randomized trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Lancet 1998;351:399-403.
21. Sisk JE, Moskowitz AJ, Whang W et al. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 1997;278: 1333-1339.
22. Konradsen HB. Quantity and avidity of pneumococcal antibodies before and up to 5 years after pneumococcal vaccination of elderly persons. Clin Infect Dis 1995;21:616-620.
23. Shapiro ED, Berg AT, Austrian R et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991;325:1453-1460.
24. Mufson MA, Hughey DF, Turner CE et al. Revaccination with pneumococcal vaccine of elderly persons 6 years after primary vaccination. Vaccine 1991;9:403-407.
25. Musher DM, Groover JE, Rowland JM et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae: Prevalence, persistence, and response to revaccination. Clin Infect Dis 1993;17:66-73.
26. Davidson M, Bulkow LR, Grabman J et al. Immunogenicity of pneumococcal revaccination in patients with chronic disease. Arch Intern Med 1994; 154:2209-2214.
27. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-33.
28. Pnu-Imune 23. (pneumococcal vaccine polyvalent) [package insert]. Pearl River, NY: Lederle Laboratories, 1999.
29. King JC, Borkowsky W, Mahidhara N et al. Group specific antibody levels surrounding invasive pneumococcal illness in children infected with human immunodeficiency virus. J Infect Dis 2000;181:1817-1821.
30. Rubins JB, Alter M, Loch J et al. Determination of seroconversions of elderly adults to all 23 capsular polysaccharides after pneumococcal vaccination. Infect Immun 1999;67:5979-5984.
31. Quataert S, Martin D, Anderson P et al. A multi-laboratory evaluation of an enzyme-linked immunoassay quantitating human antibodies to Streptococcus pneumoniae polysaccharides. Immunol Invest 2001;30:191-207.
32. Quataert SA, Kirch CS, Wiedl LJ et al. Assignment of weight-based antibody units to a human anti-pneumococcal standard reference serum, lot 89-S. Clin Diagn Lab Immunol 1995;2:590-597.
33. Jackson LA, Benson P, Sneller VP et al. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA 1999;281:243-248.
34. Romero-Steiner S, Musher DM, Cetron MS et al. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin Infect Dis 1999;29:281-288.